<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599089</url>
  </required_header>
  <id_info>
    <org_study_id>CA-PS-201</org_study_id>
    <nct_id>NCT03599089</nct_id>
  </id_info>
  <brief_title>Study of CA-008 in Bunionectomy Patients</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Safety, Pharmacokinetics and Efficacy Study of CA-008 in Subjects Undergoing Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concentric Analgesics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concentric Analgesics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel
      design study evaluating a single dose of one of three CA-008 dose levels vs. placebo injected
      during an elective bunionectomy Bunionectomy to assess post-surgical pain management and the
      need for rescue medication (oxycodone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of a single intraoperative administration of CA- 008 vs placebo in
      subjects undergoing an elective Bunionectomy .

      Secondary Objectives

        -  To evaluate the safety and tolerability of a single intraoperative administration of
           CA-008 vs. placebo in subjects undergoing an elective Bunionectomy.

        -  To evaluate the PK profile of a single intraoperative administration of CA-008 vs.
           placebo in subjects undergoing an elective Bunionectomy .

        -  To explore the efficacy of various doses of CA-008 administered intraoperatively in
           subjects undergoing an elective Bunionectomy .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">October 23, 2018</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Post-surgical pain based on the weighted sum of pain intensity (SPI) assessments over 96 hours of the NRS scores = Area Under the Curve (AUC)</measure>
    <time_frame>[time frame: 96 hours]</time_frame>
    <description>Mean area under the curve (AUC) of the Numeric Rating Scale (NRS) weighted sum of pain intensity scores (at rest) for CA-008 compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in post-surgical opioid use for CA-008 vs. placebo as measured by mean daily opioid consumption</measure>
    <time_frame>[time frame: 96 hours]</time_frame>
    <description>Percentage of subjects who are opioid-free for CA-008 compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-surgical opioid use for CA-008 vs. placebo as measured percentage of subjects who are opioid-free</measure>
    <time_frame>[time frame: 96 hours]</time_frame>
    <description>Mean total postoperative opioid consumption (in daily oral morphine equivalents) for CA-008 compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Post-surgical Pain</condition>
  <arm_group>
    <arm_group_label>CA-008 0.7 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA-008 2.1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA-008 4.2 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA-008</intervention_name>
    <description>single-dose wound infiltration prior to surgical incision closure</description>
    <arm_group_label>CA-008 0.7 mg</arm_group_label>
    <arm_group_label>CA-008 2.1 mg</arm_group_label>
    <arm_group_label>CA-008 4.2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single-dose wound infiltration prior to surgical incision closure</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30mg IV administered intraoperatively</description>
    <arm_group_label>CA-008 0.7 mg</arm_group_label>
    <arm_group_label>CA-008 2.1 mg</arm_group_label>
    <arm_group_label>CA-008 4.2 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>1000mg IV administered intraoperatively</description>
    <arm_group_label>CA-008 0.7 mg</arm_group_label>
    <arm_group_label>CA-008 2.1 mg</arm_group_label>
    <arm_group_label>CA-008 4.2 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>5mg PO prn post-surgery</description>
    <arm_group_label>CA-008 0.7 mg</arm_group_label>
    <arm_group_label>CA-008 2.1 mg</arm_group_label>
    <arm_group_label>CA-008 4.2 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>0.5% infiltration pre-surgery</description>
    <arm_group_label>CA-008 0.7 mg</arm_group_label>
    <arm_group_label>CA-008 2.1 mg</arm_group_label>
    <arm_group_label>CA-008 4.2 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult aged 18 - 75 years old

          2. American Society of Anesthesiology (ASA) physical Class 1, 2 or 3

          3. Planning elective Bunionectomy repair

          4. For both males and females: using an acceptable method of birth control

          5. If a female: not pregnant or breastfeeding

          6. Have a body mass index â‰¤ 40 kg/m2.

          7. Be willing and able to sign the informed consent form (ICF)

          8. Be able to complete study procedures and pain scales and to communicate meaningfully
             in English

          9. Be willing to undergo 17 blood draws for pharmacokinetic (PK )assessments over 24
             hours

        Exclusion Criteria:

          1. Have another painful condition, other than bunion-related pain, that may require pain
             treatment during the study period

          2. Have active skin disease or another abnormality at the anticipated site of surgery
             that could interfere with the planned surgery.

          3. Have a known allergy to chili peppers, capsaicin or the components of CA-008,
             bupivacaine HCl, ketorolac, acetaminophen or oxycodone.

          4. Have a history of significant medical, neuropsychiatric or other condition, including
             a clinically significant abnormal clinical laboratory test values

          5. Be on any medication not allowed per the protocol

          6. Within the past year have a history of illicit drug use or prescription medicine or
             alcohol abuse

          7. Have positive results on the alcohol test (breath or saliva) or urine drug screen

          8. Have previously participated in a clinical study with CA-008.

          9. Have participated in another clinical trial or used an investigational product within
             30 days or five half-lives (whichever is longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole Hodge, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Concentric Analgesics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HD Research Corp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <disposition_first_submitted>May 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 29, 2020</disposition_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

